Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PREP | P48147 | 10/20 | 0.34 |
| ▸ | FAP | Q12884 | 1/20 | 0.34 |
| ▸ | PSMB5 | P28074 | 5/20 | 0.33 |
| ▸ | F2 | P00734 | 3/20 | 0.31 |
| ▸ | PRSS1 | P07477 | 3/20 | 0.31 |
| ▸ | F10 | P00742 | 1/20 | 0.31 |
| ▸ | F7 | P08709 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13573875 | 1.00 | PREP (0.34) | PREPFAPPSMB5F2PRSS1 | |
| SCHEMBL8191092 | 0.94 | PREP (0.36) | PREPFAPPSMB5F2PRSS1 | |
| SCHEMBL8191736 | 0.94 | PREP (0.36) | PREPFAPPSMB5F2PRSS1 | |
| SCHEMBL13573876 | 0.94 | PREP (0.36) | PREPFAPPSMB5F2PRSS1 | |
| SCHEMBL13336391 | 0.94 | FAP (0.35) | PREPFAPPSMB5F2PRSS1 | |
| SCHEMBL13363192 | 0.94 | FAP (0.35) | PREPFAPPSMB5F2PRSS1 | |
| SCHEMBL8189656 | 0.93 | FAP (0.35) | PREPFAPPSMB5F2PRSS1 | |
| SCHEMBL13336393 | 0.91 | FAP (0.36) | PREPFAPPSMB5F2PRSS1 | |
| SCHEMBL13363332 | 0.91 | FAP (0.36) | PREPFAPPSMB5F2PRSS1 | |
| SCHEMBL8201674 | 0.91 | FAP (0.36) | PREPFAPPSMB5F2PRSS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100120716-A1 | MACROCYCLIC HEPATITIS C SERINE PROTEASE INHIBITORS AND USES THEREFOR | PHENOMIX CORPORATION (US) | 2010-05-13 | — | — | US | disclosed |
| US-20100120716-A1 | MACROCYCLIC HEPATITIS C SERINE PROTEASE INHIBITORS AND USES THEREFOR | PHENOMIX CORPORATION (US) | 2010-05-13 | — | — | US | disclosed |
| WO-2008070733-A2 | MACROCYCLIC HEPATITIS C SERINE PROTEASE INHIBITORS AND USES THEREFOR | PHENOMIX CORPORATION (US) | 2008-06-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100120716-A1 | MACROCYCLIC HEPATITIS C SERINE PROTEASE INHIBITORS AND USES THEREFOR | PREP, HPN, PEPD | PREP 1/4885FAP 31/4885PSMB5 1237/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.